Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787937 · ClinicalTrials.gov registry record · NA
Communicating About Nicotine Reduction in Cigarettes
A NA study of Smoking Behavior and Tobacco Products, sponsored by Georgia State University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,230
- Enrollment target
- 2
- Study locations
NCT06787937: Recruiting NA study of Smoking Behavior and Tobacco Products, sponsored by Georgia State University.
NCT06787937 is a NA study of Smoking Behavior and Tobacco Products that is actively recruiting participants, run by Georgia State University. The registered enrollment target is 1,230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (12% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06787937, a NA study of Smoking Behavior and Tobacco Products, is actively recruiting participants, sponsored by Georgia State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,230 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn how a messaging campaign about reduced nicotine cigarettes and policy, combined with the use of very low nicotine cigarettes (VLNCs), affects smoking behavior and attitudes among adult smokers. The study also aims to assess the efficacy of the messages in different populations, including smokers with past-month serious psychological distress (SPD), low socioeconomic status (SES), and those in neither category. The primary hypothesis is: exposure to messages in combination with VLNC use will lead to less cigarettes use compared to VLNCs without messages. Researchers will compare: The effects of receiving VLNCs with messages (treatment group) to receiving VLNCs without messages (control group). Participants will: Complete a baseline survey and be randomly assigned to one of two groups: treatment (VLNCs + messages) or control (VLNCs only). Attend weekly study visits for surveys, breath samples, and receive supply of VLNCs , either with or without the messaging campaign. Complete brief daily surveys through text messages.
Primary Outcome
Number of cigarettes smoked per day (study and non-study cigarettes). * Averaged number of cigarettes smoked based on 7 days' daily logs submitted through text-based survey during the last week of the trial. * Response: integer indicating number per day.
Conditions Studied
Interventions
- BEHAVIORAL VLNC messages
- BEHAVIORAL Control message
Study Locations (2)
Georgia
- Georgia State university - Atlanta
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,230 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
What NCT06787937 shows while recruiting
NCT06787937 is an interventional study that assigns participants to a tested intervention. Its 1,230 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (12% lower).
The record links to 3 conditions, with Smoking Behavior appearing as the primary indexed condition, and to 2 interventions - of which VLNC messages is the first listed.
NCT06787937 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06787937 about?
NCT06787937 is a clinical study titled "Communicating About Nicotine Reduction in Cigarettes". The goal of this clinical trial is to learn how a messaging campaign about reduced nicotine cigarettes and policy, combined with the use of very low nicotine cigarettes (VLNCs), affects smoking behavior and attitudes among adult smokers. The study also aims to assess the efficacy of the messages in ...
What is the current status of trial NCT06787937?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,230 participants. The study started on 2025-09-11. Estimated completion is 2029-01-31.
What conditions does trial NCT06787937 study?
This clinical trial studies the following conditions: Smoking Behavior, Tobacco Products, Cigarette Use.
What interventions are being tested in trial NCT06787937?
The interventions under investigation include: VLNC messages (BEHAVIORAL), Control message (BEHAVIORAL).
Who is sponsoring clinical trial NCT06787937?
This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787937 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Behavior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06787937's enrollment target sits among peer trials
1,230 82nd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI